|
J Autism Dev Disord (2008) 38:1197–1198 / 2008年8月
Ask the Expert
How Do I Decide Whether or Not to Use Medication for My Child with Autism? Should I Try Behavior Therapy First?
Lawrence Scahill1
Journal of Autism and Developmental Disorders
--------------------------------------------------------------------------------
Dear Editor:
The decision of whether to use medication or behavioral intervention in the treatment of a child with autism may be difficult in some cases and always deserves careful consideration. There is solid consensus that all children with autism need education including enriched environments for learning, speech and language training and instruction to promote social and daily living skills. There is less agreement and even controversy on the role of medication in children with autism. For example, many clinicians and parents advocate behavioral intervention rather than medication. Despite the lack of consensus on how and when to use medication in children with autism, medication use in children with autism has steadily risen over the past decade. This undisputed rise in medication use has occurred in the face of inconsistent evidence that commonly used medications are indeed effective. At the same time, the term “behavior therapy” encompasses a wide range of techniques and interventions––not all of which have supportive evidence. Thus, parental uncertainty about the use of medication or behavioral intervention in children with autism is understandable.
Recent events have brought the dilemma of medication versus behavior therapy back to center stage. In late 2006, the US Food and Drug Administration (FDA) approved the use of risperidone for the treatment of tantrums, aggression, and self-injury in children with autism indicating that this medication is safe and effective for these target problems. More recently an article published in the British journal, Lancet, showed that risperidone was no better than placebo for aggression in a group of intellectually disabled adults (Tyrer et al. 2008). At first look, it may seem difficult to reconcile the FDA approval (which was based on positive results from previous studies) and the results of the study in Lancet. Upon closer examination, however, it is possible to sort this out.
The Research Units on Pediatric Psychopharmacology (RUPP) Autism Network conducted a multisite study that was evaluated by the FDA in the decision to approve risperidone (RUPP Autism Network, 2002, 2005). In our study, risperidone was compared to placebo in 101 children with autism accompanied by severe and enduring problems of tantrums, aggression, and self-injury. By contrast, the study in Lancet included adults and only a small minority had a diagnosis of autism (Tyrer et al. 2008). Perhaps more importantly, it is not clear that the adults in the Lancet study had both severe and enduring problems with aggression. These two points have implications for the decision to use medication for aggression in children with autism. First, a medication, such as risperidone should not be used in children with mild aggression and explosive behavior that does not have an enduring pattern. Although risperidone is usually well-tolerated, it is a potent medication that may have adverse effects. In addition, if the problem behaviors are mild and not enduring, it may be difficult to determine whether the medication is actually working. Here, we may draw an analogy with fever. If a child with a low grade fever is treated with a medication––it may be difficult to detect change and even more difficult to tell if any change was due to the medication or simple passage of time. Parents and clinicians should avoid being in the position of having a child with autism on medication and being uncertain if it is working or not.
Before putting a child with autism on a medication, such as risperidone, the clinical assessment should establish the severity and pattern of the behavioral problems. A careful clinical assessment will also consider what previous treatments have been tried and are currently in place. In some cases, it may become apparent that the aggressive and explosive behavior emerged recently suggesting that it is response to new environmental demands or in response to a health problem––such as an abscessed tooth. A medication, such as risperidone should be reserved for children with moderate or greater levels of aggression, tantrums or self-injury for whom other treatments including behavior therapy have been tried and been shown to be ineffective. Finally, in children with severe behavioral problems, it may not be a matter of selecting medication or behavior therapy. Rather, it may be useful to combine medication and behavior therapy. We are now conducting a study to examine the combined effects of risperidone and a behavioral intervention.
Acknowledgments This work was supported by U10MH66764 (P.I., L. Scahill). The author would like to acknowledge the following: Allison Gavaletz, Erin Kustan.
--------------------------------------------------------------------------------
References
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism for serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2005). Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry, 162, 1361–1369.
Tyrer P., Oliver-Africano, P. C., Ahmed, Z., et al. (2008). Risperione, haloperidol and placebo in the treatment of aggressive and challenging behavior in patients with intellectual disability: a randomized trial. Lancet, 371, 57–64.
|
|